ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2891

Inflammatory Genes Are Associated with Autoantibodies in Rheumatoid Arthritis-Free Individuals Who Are at-Risk for Future Disease

Ryan W. Gan1, Kendra A. Young1, M. Kristen Demoruelle2, Michael H. Weisman3, Jane H. Buckner4, P. K. Gregersen5, Ted R. Mikuls6, James R. O'Dell6, Richard M. Keating7, Elizabeth W. Karlson8, Kevin D. Deane2, V. Michael Holers9 and Jill M. Norris1, 1Epidemiology, Colorado School of Public Health, Aurora, CO, 2Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, 3Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, 4Benaroya Research Institute at Virginia Mason, Seattle, WA, 5Genomics and Human Genetics, Feinstein Institute Medical Research and North Shore-Long Island Jewish Health System, Manhasset, NY, 6Veteran Affairs Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, 7Division of Rheumatology, Scripps Clinic, La Jolla, CA, 8Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 9Rheumatology Division, University of Colorado School of Medicine, Aurora, CO

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: autoantibodies, epidemiologic methods and genetics

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Epidemiology and Public Health IV: Rheumatoid Arthritis Pathogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose: We previously found that presence of rheumatoid arthritis(RA)-related autoantibodies is associated with systemic inflammation, and that decreased consumption of anti-inflammatory omega-3 fatty acids (n-3 FA) is associated with RA-related autoantibody positivity. We examined whether selected genes in inflammatory pathways in which n-3 FA also play a role are associated with the presence of RA-related autoantibodies in individuals without RA but at future risk for the disease.   

Methods: Participants were enrolled in The Studies of the Etiology of RA (SERA), which is a multisite observational study following a cohort of first-degree relatives of RA probands and a cohort enriched with the HLA-DR4 genetic variant, both of which are RA-free at their baseline visit. Participant DNA was screened at the Benaroya Research Institute for specific shared epitope subtypes of HLA-DR4 and HLA-DR1. Participants were positive for the shared epitope if they were either DR4 or DR1 subtype positive. Serum was measured for the following autoantibodies: anti-cyclic citrullinated peptide version 2 (CCP2), CCP3.1 (in a subset), rheumatoid factor (RF) by nephelometry, and RF isotypes (RF-IgM, RF-IgG, RF-IgA). Participants were considered positive for RA-related autoantibodies if they tested positive for any of these autoantibodies at their baseline visit.

Participants were typed for single nucleotide polymorphisms (SNPs) in Cox-2, TNFA, NF-KB, IkBkB, PPARA, and PPARG at the Broad Institute using the Sequenom platform. The association between RA-related autoantibody positivity and inflammatory genes was assessed using logistic regression, accounting for the correlation within family members, and adjusting for age at visit, sex, and race.

Results: Demographic characteristics were similar between autoantibody positive (n=306) and autoantibody negative (n=1,576) participants (Table 1). We observed a significant association between increasing number of minor alleles for Cox-2 and NF-KB and autoantibody positivity (Table 2).

Conclusion: Our results suggest that Cox-2 and NF-KB could be associated with an increased likelihood of developing RA-related autoantibodies. The association observed with Cox-2 is of interest due to the enzyme’s role in producing inflammatory lipid molecules, while the association observed with NF-KB is of interest given the potential roles that NF-KB has in the RA disease process, including cytokine production and stimulating B cell differentiation to immunoglobulin-producing B cells. These results need to be explored in further detail.

Table 1: Demographic characteristics at baseline by autoantibody (Ab) positivity.

Demographic

Ab Positive

(n=306)

Ab Negative

(n=1576)

p

Age at baseline visit (Mean ± SD)

43.9 ± 15.3

42.9 ± 13.4

0.22

Sex (% female)

71.6

68.2

0.25

Race (% NHW)

75.2

78.9

0.14

Ever Smoke (% Yes)

39.9

37.4

0.42

Current Smoker (% Yes)

12.1

10.9

0.55

Pack Years (Mean ± SD)

3.6 ± 6.8

3.5 ± 7.0

0.70

Shared Epitope (% Pos)

51.8

52.9

0.74

First-degree Relative of RA patient (%)

70.9

67.1

0.20

Table 2: Association between autoantibody positivity (CCP2, CCP3.1, or any RF) at baseline and increasing number of minor alleles (additive model). Adjusted for age, sex, and race, accounting for family correlation.

Gene

SNP

Minor Allele

MAF*

OR

95%CI

p

Cox-2

rs5275

G

0.37

1.21

1.01-1.44

0.03

TNFA 857

rs1799724

T

0.11

1.15

0.89-1.50

0.29

NF-KB

rs997476

T

0.08

1.45

1.09-1.93

<0.01

IkBkB

rs6474388

A

0.09

0.87

0.64-1.18

0.36

PPARA L162V

rs1800206

G

0.06

0.97

0.68-1.39

0.89

PPARG Pro12Ala

rs1801282

G

0.12

1.14

0.88-1.48

0.33

*Minor Allele Frequency


Disclosure:

R. W. Gan,
None;

K. A. Young,
None;

M. K. Demoruelle,
None;

M. H. Weisman,
None;

J. H. Buckner,
None;

P. K. Gregersen,
None;

T. R. Mikuls,
None;

J. R. O’Dell,
None;

R. M. Keating,
None;

E. W. Karlson,
None;

K. D. Deane,
None;

V. M. Holers,
None;

J. M. Norris,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/inflammatory-genes-are-associated-with-autoantibodies-in-rheumatoid-arthritis-free-individuals-who-are-at-risk-for-future-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology